

Brilliant Violet 605™ anti-human CD138 (Syndecan-1)

Catalog # / Size: 2382595 / 25 tests
2382600 / 100 tests

Clone: MI15

Isotype: Mouse IgG1, κ


Immunogen: A mixture of U266 and XG-1 human myeloma cell lines.

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



Human myeloma cell line U266 was stained with CD138 (clone MI15) Brilliant Violet 605™ (filled histogram) or mouse IgG1, κ Brilliant Violet 605™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The epitope recognized by MI15 is found within the ectodomain of the CD138 core protein. It has been reported that MI15 blocks the binding of clone B-B4 but not clone DL-101 by flow cytometric analysis. Clones DL-101 and MI15 exhibit differential staining patterns on *in vitro* generated plasma cells and some CD138⁺ cell lines.⁴

Additional reported applications for the relevant formats include: immunofluorescent staining¹, Western blotting², and immunohistochemical staining of formalin-fixed paraffin-embedded frozen tissue sections³.

- Application** 1. Costes V, *et al.* 1999. *Hum. Pathol.* 30:1405. (IF)
- References:** 2. Gattei V, *et al.* 1999. *Br. J. Haematol.* 104:152. (WB)
3. Bologna-Molina R, *et al.* 2008. *Oral Oncol.* 44:805. (IHC)
4. Itoua MR, *et al.* 2014. *Biomed. Res. Int.* 2014:536482.
-

Description: CD138, a member of the syndecan protein family, is a type I integral membrane heparin sulfate proteoglycan also known as Syndecan-1. Syndecan-1 participates in cell proliferation, cell migration, and cell-matrix adhesion via interaction with collagen, fibronectin, and other soluble molecules (such as FGF-basic). It is expressed on normal and malignant human plasma cells, pre-B cells, epithelial cells, and endothelial cells, but not on mature circulating B-lymphocytes. It is also expressed on some non-hematopoietic cells, including embryonic mesenchymal cells, vascular smooth muscle cells, endothelial cells, and neural cells.

- Antigen** 1. Sanderson RD, *et al.* 1992. *Cell. Regul.* 1:27.
- References:** 2. Zola H, *et al.* 2007. *Leukocyte and Stromal Cell Molecules: The CD Markers.* Wiley-Liss A John Wiley & Sons Inc, Publication.